JNJ

185.96

-1%↓

ABT

125.21

-1.57%↓

MDT

92.25

-1.86%↓

VEEV

288.4

-2.06%↓

A

145.51

-0.68%↓

JNJ

185.96

-1%↓

ABT

125.21

-1.57%↓

MDT

92.25

-1.86%↓

VEEV

288.4

-2.06%↓

A

145.51

-0.68%↓

JNJ

185.96

-1%↓

ABT

125.21

-1.57%↓

MDT

92.25

-1.86%↓

VEEV

288.4

-2.06%↓

A

145.51

-0.68%↓

JNJ

185.96

-1%↓

ABT

125.21

-1.57%↓

MDT

92.25

-1.86%↓

VEEV

288.4

-2.06%↓

A

145.51

-0.68%↓

JNJ

185.96

-1%↓

ABT

125.21

-1.57%↓

MDT

92.25

-1.86%↓

VEEV

288.4

-2.06%↓

A

145.51

-0.68%↓

Search

TG Therapeutics Inc

Open

SectorGezondheidszorg

35.02 1.68

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

33.6

Max

35.31

Belangrijke statistieken

By Trading Economics

Inkomsten

23M

28M

Verkoop

20M

141M

K/W

Sectorgemiddelde

90.051

37.461

Winstmarge

19.97

Werknemers

370

EBITDA

25M

38M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+30.6% upside

Dividenden

By Dow Jones

Volgende Winsten

3 nov 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

1B

5.6B

Vorige openingsprijs

33.34

Vorige sluitingsprijs

35.02

Nieuwssentiment

By Acuity

4%

96%

1 / 373 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

TG Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

28 okt 2025, 23:50 UTC

Populaire aandelen

Stocks to Watch: Caesars, Enphase, Mondelez, Teradyne

28 okt 2025, 23:25 UTC

Winsten

SK Hynix Posts Record Earnings on Continued AI-Chip Demand

28 okt 2025, 23:18 UTC

Winsten

Booking 3Q Sales Rise as U.S. Travel Demand Stabilizes -- Update

28 okt 2025, 22:20 UTC

Winsten

Visa Sales Jump as Consumers Keep Spending -- 2nd Update

28 okt 2025, 22:13 UTC

Winsten

Wal-Mart de Mexico Net Profit Falls in 3Q

28 okt 2025, 21:38 UTC

Winsten

Correction to Visa Sales Jump Article

28 okt 2025, 21:17 UTC

Winsten

OrthoPediatrics Wins FDA Approval for Surgery Plating System; 3Q Revenue Rises

28 okt 2025, 21:07 UTC

Winsten

Visa Sales Jump as Consumers Keep Spending -- Update

28 okt 2025, 21:02 UTC

Winsten

Mondelez Tempers Outlook as Costs Rise

28 okt 2025, 23:51 UTC

Marktinformatie

Nikkei May Rise on Easing U.S.-China Tensions -- Market Talk

28 okt 2025, 23:42 UTC

Marktinformatie

Gold Edges Lower on Possible Position Adjustments Ahead of FOMC Decision -- Market Talk

28 okt 2025, 23:02 UTC

Winsten

SK Hynix: HBM4 Shipments to Start in 4Q, Ahead of Full-Scale Sales Expansion in 2026

28 okt 2025, 23:01 UTC

Winsten

SK Hynix: Completed Discussions With Key Customers About 2026 HMB Supply

28 okt 2025, 22:46 UTC

Winsten

SK Hynix: Co. Secured Full Customer Demand for Its Entire DRAM and NAND Production for Next Yr >000660.SE

28 okt 2025, 22:45 UTC

Winsten

SK Hynix 3Q Net KRW12.6T >000660.SE

28 okt 2025, 22:44 UTC

Winsten

SK Hynix 3Q Rev KRW24.44T >000660.SE

28 okt 2025, 22:43 UTC

Winsten

SK Hynix 3Q Net Profit Beat FactSet-Compiled Consensus

28 okt 2025, 22:42 UTC

Winsten

SK Hynix 3Q Net KRW12.598T Vs. Net KRW5.753T >000660.SE

28 okt 2025, 22:40 UTC

Winsten

SK Hynix 3Q Rev KRW24.449T Vs. KRW17.573T >000660.SE

28 okt 2025, 22:40 UTC

Winsten

SK Hynix 3Q Oper Pft KRW11.383T Vs. Pft KRW7.030T >000660.SE

28 okt 2025, 22:22 UTC

Winsten

Pharmaron Beijing: Higher Contributions From Clinical-Development Services Supported Results >300759.SZ

28 okt 2025, 22:22 UTC

Winsten

Pharmaron Beijing: Higher Contributions From Laboratory Services Supported Results >300759.SZ

28 okt 2025, 22:22 UTC

Winsten

Pharmaron Beijing 3Q Net CNY439.52M, Up 42.5% on Year >300759.SZ

28 okt 2025, 22:20 UTC

Winsten

Pharmaron Beijing 3Q Rev CNY3.64B, Up 13.4% on Year >300759.SZ

28 okt 2025, 22:02 UTC

Winsten

Review & Preview: Earnings Extravaganza -- Barrons.com

28 okt 2025, 21:42 UTC

Marktinformatie
Winsten

Global Equities Roundup: Market Talk

28 okt 2025, 21:42 UTC

Marktinformatie
Winsten

Mondelez Says Cocoa Costs Peaked Heading Into Spooky Season -- Market Talk

28 okt 2025, 21:20 UTC

Winsten

Wal-Mart de Mexico 3Q EBITDA MXN25.27B, Up 3.3% on Year

28 okt 2025, 21:19 UTC

Winsten

Wal-Mart de Mexico 3Q Rev MXN241.52B, Up 4.9% on Year

28 okt 2025, 21:18 UTC

Winsten

Wal-Mart de Mexico 3Q Net MXN11.75B, Down 9.2% on Year

Peer Vergelijking

Prijswijziging

TG Therapeutics Inc Prognose

Koersdoel

By TipRanks

30.6% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 44 USD  30.6%

Hoogste 60 USD

Laagste 11 USD

Gebaseerd op 4 Wall Street-analisten die 12-maands prijsdoelen bieden voor TG Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

4 ratings

3

Buy

0

Hold

1

Sell

Technische score

By Trading Central

N/A / 34.86Steun & Weerstand

Korte Termijn

Very Strong Bearish Evidence

Gemiddeld Termijn

Bearish Evidence

Lange Termijn

Bullish Evidence

Sentiment

By Acuity

1 / 373 Rangschikking in Gezondheidszorg

Nieuwssentiment

Zeer Sterk Bearish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over TG Therapeutics Inc

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.
help-icon Live chat